Open Access

Identification of glutathione S‑transferase π 1 as a prognostic proteomic biomarker for multiple myeloma using proteomic profiling

  • Authors:
    • Jing Zhao
    • Meihua Wang
    • Pengcheng He
    • Ying Chen
    • Xiaoning Wang
    • Mei Zhang
  • View Affiliations

  • Published online on: January 21, 2020     https://doi.org/10.3892/ol.2020.11321
  • Pages: 2153-2162
  • Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Multiple myeloma (MM) is a B‑cell hematological malignancy with monoclonal plasma cell proliferation in the bone marrow. Early diagnosis of MM remains difficult due to the lack of specific symptoms and biomarkers. In the present study, matrix‑assisted laser desorption/ionization time‑of‑flight mass spectrometry and the ClinProt system was used to detect potential biomarkers for MM from the bone marrow samples of 30 patients and 30 healthy controls. A total of 10 of the most significantly differentiated peaks between the patients and controls were identified. When patients with MM were compared with controls, 6 peaks with m/z values of 1,779.24, 1,866.32, 2,022.36, 2,878.9, 4,417.76 and 7,155.38 were upregulated, and 4 peaks with m/z values of 1,466.54, 1,520.02, 1,546.53 and 2,991.05 were downregulated. Of these 10 peaks, 4 peaks (pk 8, 1,866.32 Da; pk 15, 2,878.90 Da; pk 17, 2,991.05 Da; and pk 3, 1,520.02 Da) were further sequenced and identified using liquid chromatography/electrospray ionization‑tandem mass spectrometry (LC‑ESI‑MS/MS). Furthermore, the expression of fibronectin 1 and glutathione S‑transferase π 1 (GSTP1) were validated in patients with MM via ELISAs. Clinical data and statistical analysis indicated that GSTP1 expression was closely associated with the clinical stage of patients with MM. High GSTP1 levels were an independent risk factor for worse prognosis in patients with MM. These results demonstrate that GSTP1 may be a novel biomarker for early diagnosis, prognosis and monitoring of minimal residual disease in MM.

Related Articles

Journal Cover

March 2020
Volume 19 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Zhao, J., Wang, M., He, P., Chen, Y., Wang, X., & Zhang, M. (2020). Identification of glutathione S‑transferase π 1 as a prognostic proteomic biomarker for multiple myeloma using proteomic profiling. Oncology Letters, 19, 2153-2162. https://doi.org/10.3892/ol.2020.11321
MLA
Zhao, J., Wang, M., He, P., Chen, Y., Wang, X., Zhang, M."Identification of glutathione S‑transferase π 1 as a prognostic proteomic biomarker for multiple myeloma using proteomic profiling". Oncology Letters 19.3 (2020): 2153-2162.
Chicago
Zhao, J., Wang, M., He, P., Chen, Y., Wang, X., Zhang, M."Identification of glutathione S‑transferase π 1 as a prognostic proteomic biomarker for multiple myeloma using proteomic profiling". Oncology Letters 19, no. 3 (2020): 2153-2162. https://doi.org/10.3892/ol.2020.11321